Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5′-deoxy-5-fluorouridine against adenocarcinoma 755 in mice: Correlation with pharmacokinetics of plasma 5-fluorouracil levels

Abstract

5′-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) was pursued in BDF 1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells. Half-life ( t 1 2 ) values for the elimination of DFUR and 5-fluorouracil (5-FU) from plasma following DFUR (100 mg/kg) administration were about 0.80 and 0.39 hr, respectively. Plasma 5-FU AUC (area under the curve) values following oral DFUR (100 mg/kg) was 0.224 μg·hr/ml. If DFUR (100 mg/kg) was combined with BVDU (10 mg/kg) the t 1 2 and AUC values for 5-FU increased from 0.39 to 1.24 hr, and from 0.224 to 1.699 μg·hr/ml, respectively. Thus, BVDU significantly increased the plasma levels of 5-FU. It had no effect on the plasma levels of DFUR. At 100 mg/kg, DFUR did not show a significant antitumor activity. At 500 mg/kg it effected a 90% inhibition in tumor growth. When combined with BVDU (10 mg/kg), DFUR at 100, 200 and 300 mg/kg reduced tumor growth by 96, 100 and 100%, respectively. The antitumor activity achieved by DFUR, in the presence or absence of BVDU, correlated highly significantly with the AUC values for plasma 5-FU.